AstraZeneca Ventures is the CVC arm of pharmaceutical giant AstraZeneca (founded 1999, Cambridge UK). Invests Seed-Series C in biotech/medtech/digital health aligned w/ oncology, CV/metabolic, respiratory/immunology, rare disease. Portfolio incl. Huma (Series D 2024), SixPeaks Bio (weight management, acquired 2025). Operates BioVentureHub in Gothenburg (incubation model). Also backs companies via AstraZeneca-CICC Healthcare Fund for China investments. Historically $400m MedImmune Ventures fund (2002-2016). Value-add: pharma expertise, regulatory knowledge, access to AZ infrastructure.
Investment Focus
Investment Thesis
Pharma CVC backing biotech seed-Series C. £1m-£20m cheques. Focus: oncology, cardiovascular/renal/metabolism, respiratory/immunology, rare disease. Also operates AstraZeneca-CICC Healthcare Fund (China co-invest) & BioVentureHub (Sweden innovation hub). Historically used $400m MedImmune Ventures (2002-2016, now liquidated). Prefers therapeutic alignment w/ core pipeline. Also acquires optioned companies (e.g. SixPeaks £110m+milestone 2024-25).
Interested in connecting?
Visit their website or reach out directly.